L-MYC PATHWAY TARGETING AS A TREATMENT FOR SMALL CELL LUNG CANCER

摘要

L-Myc pathway targeting treatments as a treatment for small cell lung cancer (SCLC) are described. The treatments can be genetic and/or pharmacologic and can particularly target L-Myc, L-Myc's partner protein MAX and/or RNA Polymerase I. Specifically, the disclosure provides a method of treating small cell lung cancer (SCLC) in a subject in need thereof comprising administering a therapeutically effective amount of an L-Myc inactivator to the subject, wherein the L-Myc inactivator comprises CX-5461, Actinomycin D, or a guide RNA.